Nutra Pharma unit renews CDC contract

Florida, USA-based biotechnology firm Nutra Pharma, which is developing drugs for HIV and multiple sclerosis, says that its wholly-owned drug discovery subsidiary, ReceptoPharm, has renewed its collaborative agreement with the Centers for Disease Control and Prevention (CDC) to study RPI-78M and RPI-MN as a possible therapy for rabies. RPI-78M is ReceptoPharm's leading drug candidate for the treatment of autoimmune and neurological disorders and RPI-MN is the firm's leading antiviral drug candidate.

"This collaboration with the CDC allows us to analyze various formulas for both RPI-78M and RPI-MN as possible treatments for rabies," explained Paul Reid, chief executive of ReceptoPharm. "Our goal with this study is to better understand the mechanism of action of our leading drug candidates and to determine their potential for treating advanced rabies infections," he concluded.